Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

e Company's lead candidate, cethromycin, is a novel NDA-stage once-a-day oral antibiotic for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials, the adequacy of our clinical results, the timing and terms of any commercial partnership, and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's fili
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 BioTech News Coverage: ... and results of studies and trials.  Companies in focus ... (NYSE: LLY ), Gilead Sciences Inc. (NASDAQ: ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... prodrug therapeutics for the treatment of cancer, announced that ...
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... 2014 About POCT ... a clinical laboratory. It helps in making fast ... and medication. POCT is gaining popularity due to ... such as diabetes, heart disease, and obesity. It ... standardized to minimize errors during the diagnosis of ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... by Rice University has brought a wealth of new information ... The current issue of the American Chemical Society journal ... the Rice lab of chemist Bruce Weisman to understand how ... in this case, the light they emit at near-infrared ...
... Realty Trust, Inc. (NYSE: BMR ) today announced ... ended December 31, 2011 after the market closes on Wednesday, ... and Chief Executive Officer, Kent Griffin, President, Matt McDevitt, Executive ... host an investor conference call at 10:00 a.m. Pacific Time ...
... DURHAM, N.C., Jan. 31, 2012  Argos Therapeutics Inc., ... immune monitoring analysis of AGS-003-006, a Phase 2 ... with sunitinib in patients with advanced renal cell ... correlation between anti-tumor memory T cell responses and ...
Cached Biology Technology:Perfect nanotubes shine brightest 2BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... are two root causes of a type of diabetes associated ... a clinical trial, may guide development of new treatments or ... Almost half of patients with CF will develop diabetes by ... their teens. In addition to the health problems caused by ...
... CORVALLIS, Ore. Diatoms, tiny marine life forms that ... biofuel production from algae truly cost-effective because they ... biomedical products and even health foods. Engineers at ... the envelope a bit. But it,s not science fiction ...
... and pregnant, your baby isn,t destined to a life of ... online in The FASEB Journal . In ... fat intake during pregnancy to a moderate level is enough ... they found that a protein called "SIRT1" rewrites a developing ...
Cached Biology News:Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2
... Cellject Uno Electroporator is a simple, ... optimum efficiencies in bacterial and yeast ... one of two voltages and either ... mm cuvettes. On pressing the pulse ...
Request Info...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
Biology Products: